Regeneron sued over antibody protein used to treat Trump’s COVID-19 symptoms

Regeneron Pharmaceuticals is facing claims that its “antibody cocktail”, which was administered to President Donald Trump to treat his COVID-19 symptoms, was developed with the unauthorised use of a fluorescent protein.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Alnylam and Regeneron unveil RNAi partnership

9 April 2019 Pharmaceutical companies Alnylam and Regeneron will collaborate on the development and commercialisation of RNA interference therapeutics.

Americas

Kilpatrick Townsend hires litigation team from DLA Piper

19 October 2020 Kilpatrick Townsend & Stockton has strengthened its life sciences expertise with the addition of a patent litigation team, that includes four litigators from DLA Piper.

Big Pharma

English court resumes Amgen cholesterol patent suit

23 October 2020 The English High Court has lifted a stay on Amgen’s lawsuit which accused Sanofi-Aventis and Regeneron of infringing a patent covering pharmaceuticals which treat elevated cholesterol levels.

More on this story

Americas

Alnylam and Regeneron unveil RNAi partnership

9 April 2019 Pharmaceutical companies Alnylam and Regeneron will collaborate on the development and commercialisation of RNA interference therapeutics.

Americas

Kilpatrick Townsend hires litigation team from DLA Piper

19 October 2020 Kilpatrick Townsend & Stockton has strengthened its life sciences expertise with the addition of a patent litigation team, that includes four litigators from DLA Piper.

Big Pharma

English court resumes Amgen cholesterol patent suit

More on this story

Americas

Alnylam and Regeneron unveil RNAi partnership

9 April 2019 Pharmaceutical companies Alnylam and Regeneron will collaborate on the development and commercialisation of RNA interference therapeutics.

Americas

Kilpatrick Townsend hires litigation team from DLA Piper

19 October 2020 Kilpatrick Townsend & Stockton has strengthened its life sciences expertise with the addition of a patent litigation team, that includes four litigators from DLA Piper.

Big Pharma

English court resumes Amgen cholesterol patent suit